Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance

Molecular Cancer Therapeutics

Volumn 8, Issue 8, 2009, Pages 2086-2095

  Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9,10 DIDEHYDROEPOTHILONE D; ANTINEOPLASTIC AGENT; BETA TUBULIN; CAPECITABINE; CYCLOSPORIN A; DJ 927; DOCETAXEL; DOXORUBICIN; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; ER 086526; ERIBULIN; HALICHONDRIN B; IXABEPILONE; MICROTUBULE ASSOCIATED PROTEIN 4; MICROTUBULE DESTABILIZING AGENT; MICROTUBULE STABILIZING AGENT; MULTIDRUG RESISTANCE PROTEIN 1; NAVELBINE; NSC 707389; PACLITAXEL; STATHMIN; TARIQUIDAR; TAU PROTEIN; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINFLUNINE; ZOSUQUIDAR;

ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CELL CYCLE ARREST; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; HEAD AND NECK CARCINOMA; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MICROTUBULE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEOPLASM; NEUTROPENIA; NONHUMAN; OVARY CARCINOMA; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECOMMENDED DRUG DOSE; SHORT SURVEY; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; TRANSITIONAL CELL CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; HUMANS; MICROTUBULES; MITOSIS; NEOPLASMS; TAXOIDS; TUBULIN MODULATORS; VINCA ALKALOIDS;

EID: 68849087436     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0366     Document Type: Short Survey

References (86)

1. Nogales E. Structural insight into microtubule function. Annu Rev Biophys Biomol Struct 2001;30:397-420.
2. Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 2005;5:65-71.
3. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
4. Lobert S, Vulevic B, Correia JJ. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry 1996;35:6806-14.
5. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002;2:1-17.
6. Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-7.
7. Nogales E, Wolf SG, Khan IA, Ludueña RF, Downing KH. Structure of tubulin at 6.5 A and location of the taxol-binding site. Nature 1995;375:424-7.
8. Rowinsky EK. Antimicrotubule agents. In: Chabner B, Longo DL, editors. Cancer chemotherapy and biotherapy: Principles and practice. Philadelphia: Lippincott Williams & Wilkins; 2005, p. 237-82.
9. Bristol-Myers Squibb Company; Princeton (NJ). Prescribing information taxol (paclitaxel) injection. July 2007.
10. Sanofi-Aventis U.S. LLC; Bridgewater (NJ). Prescribing information taxotere (docetaxel) injection concentrate. 2007.
11. Abraxis Oncology; Bridgewater (NJ). Prescribing information for abraxane for injectable suspension (paclitaxel protein-bound particles for injectable suspension)(albumin-bound). Version 2005 Jan 7.
12. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27.
13. Pusztai L, Wagner P, Ibrahim N, et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 2005;104:682-91.
14. Fracasso PM, Goldstein LJ, De Alwis DP, et al. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin Cancer Res 2004;10:7220-8.
15. Giannakakou P, Sackett DL, Kang YK, et al. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997;272:17118-25.
16. Lu Q, Luduena RF. In vitro analysis of microtubule assembly of isotypically pure tubulin dimers. Intrinsic differences in the assembly properties of α β II, α β III, and α β IV tubulin dimers in the absence of microtubule-associated proteins. J Biol Chem 1994;269:2041-7.
17. Kamath K, Wilson L, Cabral F, Jordan MS. βIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 2005;280:12902-7.
18. Seve P, Isaac S, Tredan O, et al. Expression of class III {β}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005;11:5481-6.
19. Pusztai L. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann Oncol 2007;18:xii15-20.
20. Paradiso A, Mangia A, Chiratti A, et al. Biomarkers predicative for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol 2005;16:iv14-9.
21. Tommasi S, Mangia A, Lacalamita R, et al. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of β-tubulins. Int J Cancer 2007;120:2078-85.
22. Noguchi S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 2006;97:813-20.
23. Dumontet C, Isaac S, Souquet PJ, et al. Expression of class III β tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 2005;92:E25-30.
24. Mozzetti S, Ferlini C, Concolino P, et al. Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005;11:298-305.
25. Alli E, Bash-Babula J, Yang JM, Hait WN. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res 2002;62:6864-9.
26. Zhang CC, Yang JM, White E, Murphy M, Levine A, Hait WN. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene 1998;16:1617-24.
27. Zhang CC, Yang JM, Bash-Babula J, et al. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4. Cancer Res 1999;59:3663-70.
28. Verrills NM, Po'uha ST, Liu ML, et al. Alterations in γ-actin and tubulin-targeted drug resistance in childhood leukemia. J Natl Cancer Inst 2006;98:1363-74.
29. Pusztai L, Jeong J, Gong Y, et al. Evaluation of microtubule associated protein T expression as prognostic and predictive marker in the NSABP-B 28 randomized clinical trial [abstract 54]. Presented at the 31st Annual SABCS Meeting; 2008.
30. Reichenbach H, Höfle G. Discovery and development of the epothilones: a novel class of antineoplastic drugs. Drugs R D 2008;9:1-10.
31. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995;55:2325-33.
32. Altmann KH, Wartmann M, O'Reilly T. Epothilones and related structures - a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 2000;1470:M79-91.
33. Kamath K, Jordan MA. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest. Cancer Res 2003;63:6026-31.
34. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH. The binding mode of epothilone A on α,β-tubulin by electron crystallography. Science 2004;305:866-9.
35. Bode CJ, Gupta ML, Jr., Reiff EA, Suprenant KA, Georg GI, Himes RH. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry 2002;41:3870-4.
36. Fumoleau P, Coudert B, Isambert N, Ferrant E. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol 2007;18:v9-15.
37. Fojo T, Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol 2007;18:v3-8.
38. Lee JJ, Swain SM. The epothilones: translating from the laboratory to the clinic. Clin Cancer Res 2008;14:1618-24.
39. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001;7:1429-37.
40. Kolman A. BMS-310705 Bristol-Myers Squibb/GBF. Curr Opin Investig Drugs 2004;5:1292-7.
41. Lee FY, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol 2009;63:201-12.
42. Lee FY, Borzilleri R, Fairchild CR, et al. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol 2008;63:157-66.
43. Fornier MN. Ixabepilone, first in a new class of antineoplastic agents: the natural epothilones and their analogues. Clin Breast Cancer 2007;7:757-63.
44. Vahdat L. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Oncologist 2008;13:214-21.
45. Altmann KH. The chemistry and biology of epothilones - lead structures for the discovery of improved microtubule inhibitors. In: Liang X-T, Fang W-S, editors. Medicinal chemistry of bioactive natural products. Hoboken (NJ): John Wiley & Sons, Inc.; 2006, p. 1-34.
46. Schimmer AD, Hedley DW, Penn LZ, Minden MD. Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. Blood 2001;98:3541-53.
47. Perkins CL, Fang G, Kim CN, Bhalla KN. The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res 2000;60:1645-53.
48. Janssen K, Pohlmann S, Jänicke RU, Schulze-Osthoff K, Fischer U. Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during paclitaxel treatment. Blood 2007;110:3662-72.
49. Guo F, Nimmanapalli R, Paranawithana S, et al. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood 2002;99:3419-26.
50. Griffin D, Wittmann S, Guo F, et al. Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells. Gynecol Oncol 2003;89:37-47.
51. Rojas-Espaillet LA, Uyar D, Grabowski D, et al. Apoptotic pathways induced by ixabepilone in paclitaxel-refractory ovarian carcinoma cells. Proc Am Assoc Cancer Res 2005;46:5318.
52. Yamaguchi H, Chen J, Bhalla K, Wang HG. Regulation of Bax activation and apoptotic response to microtubule-damaging agents by p53 transcription-dependent and -independent pathways. J Biol Chem 2004;279:39431-7.
53. Pivot X, Villanueva C, Chaigneau L, et al. Ixabepilone, a novel epothilone analog in the treatment of breast cancer. Expert Opin Investig Drugs 2008;17:593-9.
54. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone analog, in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407-14.
55. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007;25:3399-406.
56. Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25:3415-20.
57. Baselga J, Zambetti M, Llombart-Cussac A, et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer: efficacy and safety analyses and identification of biomarkers predictive of response. J Clin Oncol 2008. Epub 2008 15 Dec.
58. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-7.
59. Denduluri N, Swain SM. Ixabepilone for the treatment of solid tumors: a review of clinical data. Expert Opin Investig Drugs 2008;17:423-35.
60. Abrey L, Wen PY, Govindan R, et al. Activity of patupilone for the treatment of recurrent or progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II study. J Clin Oncol 2007;25:18058.
61. Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer [accessed 2009 Jan 19]. Available from: http://clinicaltrials.gov/ct2/show/NCT00262990.
62. Overmoyer B, Waintraub S, Kaufman PA, et al. Phase II trial of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer. J Clin Oncol 2005;23:778.
63. Villalona-Calero M, Goel S, Schaaf L, et al. First-in-human phase I trial of a novel epothilone, KOS-1584. J Clin Oncol 2006;24:2003.
64. Zhou Y, Zhong Z, Liu F, et al. KOS-1584: a rationally designed epothilone D analog with improved potency and pharmacokinetic (PK) properties. Proc Am Assoc Cancer Res 2005;46:2535.
65. Study to evaluate KOS-1584 in patients with advanced or metastatic (stage IIIB/IV) non-small cell lung cancer [accessed 2009 Jan 19]. Available from: http://clinicaltrials.gov/ct2/show/NCT00651508.
66. Kruczynski A, Hill BT. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol Hematol 2001;40:159-73.
67. Bennouna J, Delord JP, Campone M, Nguyen L. Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res 2008;14:1625-32.
68. Bennouna J, Campone M, Delord JP, Pinel MC. Vinflunine: a novel antitubulin agent in solid malignancies. Expert Opin Investig Drugs 2005;14:1259-67.
69. Culine S, Theodore C, De Santis M, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006;94:1395-401.
70. Petrylak DP, Vaughn DJ, Srinivas S, et al. Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium (TCCU). Barcelona (Spain): Presented at the European Cancer Conference; September 27, 2007.
71. Campone M, Cortes-Funes H, Vorobiof D, et al. Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Br J Cancer 2006;95:1161-6.
72. Krzakowski M, Douillard J, Ramlau R, et al. Phase III study of vinflunine versus docetaxel in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a platinum-containing regimen. Proc Am Soc Clin Oncol 2007;25:7511.
73. Talbot DC, Margery J, Dabouis G, et al. Phase II study of vinflunine in malignant pleural mesothelioma. J Clin Oncol 2007;25:4751-6.
74. Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005;4:1086-95.
75. Kuznetsov G, Towle MJ, Cheng H, et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004;64:5760-6.
76. Dabydeen DA, Burnett JC, Bai R, et al. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol 2006;70:1866-75.
77. Blum J, Pruitt B, Fabian CJ, et al. Phase II study of eribulin mesylate (E7389) halichondrin b analog in patients with refractory breast cancer. J Clin Oncol 2007;25:1034.
78. Spira AI, Iannotti NO, Savin MA, et al. Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25:7546.
79. Molife R, Cartwright TH, Loesch DM, et al. Phase II multicenter, two-stage study of E7389 in patients with hormone refractory prostate cancer with advanced and/or metastatic disease stratified by prior chemotherapy. J Clin Oncol 2007;25:15513.
80. E7389 versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes and refractory to the most recent chemotherapy [accessed 2009 Jan 19]. Available from: http://clinicaltrials.gov/ct2/show/NCT00337103.
81. E7389 versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer [accessed 2009 Jan 19]. Available from: http://clinicaltrials.gov/ct2/show/NCT00388726.
82. Shionoya M, Jimbo T, Kitagawa M, Soga T, Tohgo A. DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci 2003;94:459-66.
83. Evans T, Dobrila R, Berardi R, et al. A phase II study of DJ-927 as second-line therapy in patients (pts) with advanced gastric cancer (GC) who have failed a 5-FU non taxane based regimen. J Clin Oncol 2006;24:4081.
84. Rhee J, Lee F, Saif MW, et al. Phase II trial of DJ-927 as a second-line treatment for colorectal cancer demonstrates objective responses. Proc Am Soc Clin Oncol 2005;23:3654.
85. Lobert S, Frankfurter A, Correia JJ. Energetics of vinca alkaloid interactions with tubulin isotypes: Implications for drug efficacy and toxicity. Cell Motil Cytoskeleton 1998;39:107-21.
86. Derry WB, Wilson L, Khan IA, Luduena RF, Jordan MA. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified β-tubulin isotypes. Biochemistry 1997;36:3554-62.